A combined nutritional risk index and carcinoembryonic antigen score predicts the outcome in radically resected colorectal cancer

ANZ J Surg. 2024 Oct;94(10):1818-1822. doi: 10.1111/ans.19161. Epub 2024 Jul 17.

Abstract

Background: Nutritional risk index (NRI) and carcinoembryonic antigen (CEA) are useful prognostic markers in colorectal cancer (CRC); however, the prognostic value of a combination of the NRI and CEA, namely, the NRI and CEA score (NCS), needs further investigation.

Methods: Stage I-III CRC patients were collected and then divided into three subgroups by counting the NCS: NCS 1: high NRI with normal CEA; NCS 2: high NRI with elevated CEA or low NRI with normal CEA; and NCS 3: low NRI with elevated CEA. The differences in outcome, counted as disease-free survival (DFS) and overall survival (OS), were tested among the subgroups.

Results: A total of 285 patients were enrolled, with 108 in NCS 1, 118 in NCS 2 and 59 in NCS 3. Patient features, including age, tumour deposit, T stage, N stage and TNM stage, were significantly different in the NCS subgroups. Both the DFS (log-rank = 26.06, P<0.001) and OS (log-rank = 39.10, P<0.001) were significant in different NCS subgroups, even in maximum tumour diameter ≤4 cm cases (DFS: log-rank = 21.42, P<0.001; OS: log-rank = 30.95, P<0.001), and NCS 1 patients displayed the best outcome compared with the rest of the subgroups. NCS was also found to be an independent risk factor for both DFS and OS.

Conclusions: NCS was a useful prognostic indicator in stages I-III CRC patients.

Keywords: carcinoembryonic antigen; colorectal cancer; nutritional risk index; outcome; survival.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoembryonic Antigen* / blood
  • Colorectal Neoplasms* / mortality
  • Colorectal Neoplasms* / pathology
  • Colorectal Neoplasms* / surgery
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging*
  • Nutrition Assessment*
  • Nutritional Status
  • Prognosis
  • Retrospective Studies
  • Risk Assessment / methods
  • Treatment Outcome

Substances

  • Carcinoembryonic Antigen